U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Grand Rounds: Evaluating Mutagenicity by Error-corrected Sequencing - 03/14/2024
  1. About Science & Research at FDA

Webcast | Virtual

Event Title
FDA Grand Rounds: Evaluating Mutagenicity by Error-corrected Sequencing
March 14, 2024

Date:
March 14, 2024
Time:
12:00 p.m. - 1:00 p.m. ET
Image
FDA Grand Rounds: Evaluating Mutagenicity by Error-corrected Sequencing image

About the Speaker

Javier Revollo

Javier Revollo, Ph.D.
Research Biologist
Division of Genetic and Molecular Toxicology
National Center for Toxicological Research (NCTR)
U.S. Food and Drug Administration (FDA) 

About the Speaker

Dr. Revollo is a Research Biologist and Principal Investigator in the Division of Genetic and Molecular Toxicology at the National Center for Toxicological Research. He studied at the University of Wisconsin-Madison (B.S. in Genetics, 1997-2000), Washington University in St. Louis (Ph.D. in Molecular Cell Biology, 2001-2006), and pursued postdoctoral studies at the National Institutes of Health (NIH) (2007-2012). Javier joined the FDA due to his expertise in genomics, DNA sequencing, and bioinformatics. His research efforts at the FDA have focused on the development of DNA sequencing methods and bioinformatic algorithms to study somatic mutations.

About the Presentation

Somatic mutations are permanent and heritable genetic alterations that increase cancer risk. They can occur spontaneously but most often result from DNA damage induced by the environment (e.g., sunlight) or genotoxic compounds (e.g., chemical mutagens). Conventional mutation detection assays can only indirectly estimate somatic mutation frequencies through reporter genes, which can limit the implementation of such assays. To overcome this challenge, error-corrected sequencing methods and bioinformatic algorithms capable of directly identifying somatic mutations from any DNA samples are being developed and refined. During this lecture, research efforts in these areas will be explored.

Learning Objectives

  • Compare and contrast germline and somatic mutations.
  • Discuss the importance of identifying somatic mutations.
  • Describe how DNA sequencing can be used to identify somatic mutations.

Event Materials

Activity Announcement for FDA Grand Rounds – March 14, 2024: https://ceportal.fda.gov/index.cfm?do=cus.runEventReport&reportName=EventAnnouncementForm&style=2&preview=1&eventId=8482 

Webcast Recording

https://fda.zoomgov.com/rec/share/Oa4xa4eLNb4kyh2IKm1GIa3tcjFBW1R8W6bkW9kGu_yU7xRnUCnjQefdTz18CUII._KSJMia-2REQYceL 
 

Back to Top